SCHEMBL5744811

SCHEMBL5744811

CCC(=O)N1CCC(N)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 1/20 0.49
GNAO1 P09471 1/20 0.49
GNAI1 P63096 1/20 0.49
CHRNB2 P17787 3/20 0.46
CHRNA3 P32297 3/20 0.46
CHRNA4 P43681 3/20 0.46
CHRNB3 Q05901 1/20 0.46
CHRNA6 Q15825 1/20 0.46
EPHX2 P34913 5/20 0.45
CHRNB4 P30926 2/20 0.44
CHRNA7 P36544 2/20 0.44
KDM1A O60341 1/20 0.43
MAOA P21397 1/20 0.43
ALDH1A1 P00352 1/20 0.42
DPP4 P27487 2/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
MCHR1 Q99705 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403317 1.00 GNAI3 (0.49) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL15731364 1.00 GNAI3 (0.49) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL3402450 0.89 MEN1 (0.46) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL3402896 0.89 MEN1 (0.46) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL3399867 0.89 MEN1 (0.46) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL11717 0.88 GNAI3 (0.61) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL22474753 0.87 EPHX2 (0.45) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL13459961 0.85 GNAI3 (0.58) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL14275539 0.85 GNAI3 (0.58) GNAI3GNAO1GNAI1CHRNB2CHRNA3
SCHEMBL3403409 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117534672-A New preparation method of APDS (active pharmaceutical ingredient) therapeutic drug 北京康立生医药技术开发有限公司 2024-02-09 CN claimed
CN-117534672-A New preparation method of APDS (active pharmaceutical ingredient) therapeutic drug 北京康立生医药技术开发有限公司 2024-02-09 CN disclosed
US-11130758-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-09-28 US disclosed
US-20200347050-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-11-05 US disclosed
US-9938281-B2 Purine inhibitors of human phosphatidylinositol 3-kinase delta MERCK SHARP & DOHME CORP. (US) 2018-04-10 US disclosed
US-20160207926-A1 PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA MERCK SHARP & DOHME CORP. (US) 2016-07-21 US disclosed
CN-103282025-A Melt-extruded solid dispersions containing apoptosis-inducing agents ABBVIE INC 2013-09-04 CN disclosed
CN-103167867-A Solid dispersions containing an apoptosis-inducing agent ABBOTT LAB 2013-06-19 CN disclosed
CN-103153993-A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBOTT LAB 2013-06-12 CN disclosed
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-8026368-B2 Hydrazide compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-27 US disclosed
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-08 US disclosed
US-7332509-B2 Heterocyclic amides, a process for their preparation, compositions comprising them and their use MERIAL LIMITED (US) 2008-02-19 US disclosed
EP-1434485-B1 NICOTINIC ACID-HETEROCYCLYL-AMIDES AND ANALOGOUS PYRIMIDINE DERIVATIVES FOR USE AS PESTICIDES MERIAL LTD (US) 2007-05-16 EP disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
EP-1651635-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS Pfizer Limited (GB) 2006-05-03 EP disclosed
WO-2005009989-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed
WO-2005009989-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed
US-20050020587-A1 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 GNAI3 226/4885GNAO1 787/4885GNAI1 196/4885
US-20050020587-A1 Nicotinamide derivatives useful as PDE4 inhibitors PDE4A, PDE4B, PDE4D GNAI3 242/4885GNAO1 158/4885GNAI1 214/4885
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, THPO, PTAFR GNAI3 3256/4885GNAO1 1521/4885GNAI1 2424/4885
US-20160207926-A1 PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PI4KA GNAI3 167/4885GNAO1 489/4885GNAI1 123/4885
US-20200347050-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 GNAI3 648/4885GNAO1 1538/4885GNAI1 691/4885
US-11130758-B2 Tetrahydropyrazolopyrimidine compounds SSB, TLR8, TLR9 GNAI3 648/4885GNAO1 1538/4885GNAI1 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.